1.Is Omalizumab a Problem-Solving Remedy in Severe Asthma?.
Allergy, Asthma & Immunology Research 2018;10(2):95-96
No abstract available.
Asthma*
;
Omalizumab*
2.Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema.
Ali KUTLU ; Ercan KARABACAK ; Ersin AYDIN ; Selim AKARSU ; Sami ÖZTÜRK
Annals of Dermatology 2016;28(3):381-382
No abstract available.
Angioedema*
;
Angioedemas, Hereditary*
;
Humans
;
Omalizumab*
3.A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria.
Anna Cecilie LEFEVRE ; Mette DELEURAN ; Christian VESTERGAARD
Annals of Dermatology 2013;25(2):242-245
No abstract available.
Antibodies, Anti-Idiotypic
;
Antibodies, Monoclonal, Humanized
;
Urticaria
;
Omalizumab
4.Combination of omalizumab and bee venom immunotherapy: does it work?
Insu YILMAZ ; Sakine Nazik BAHÇECIOĞLU ; Murat TÜRK
Asia Pacific Allergy 2018;8(1):e2-
Bee venom immunotherapy (b-VIT) can be combined with omalizumab therapy in order to suppress systemic reactions developing due to b-VIT itself. Omalizumab acts as a premedication and gains time for the immunotherapy to develop its immunomodulatory effects. However, the combination of omalizumab and b-VIT is not always effective enough. Herein we present a patient in whom successful immunotherapy cannot be achieved with combination of omalizumab to b-VIT.
Anaphylaxis
;
Bee Venoms
;
Bees
;
Humans
;
Immunotherapy
;
Omalizumab
;
Premedication
5.Personalized Medicine in Allergy.
Matteo FERRANDO ; Diego BAGNASCO ; Gilda VARRICCHI ; Stefano BERNARDI ; Alice BRAGANTINI ; Giovanni PASSALACQUA ; Giorgio Walter CANONICA
Allergy, Asthma & Immunology Research 2017;9(1):15-24
Allergic disease is among the most common pathologies worldwide and its prevalence has constantly increased up to the present days, even if according to the most recent data it seems to be slightly slowing down. Allergic disease has not only a high rate of misdiagnosis and therapeutic inefficacy, but represents an enormous, resource-absorbing black hole in respiratory and general medicine. The aim of this paper is to summarize principal therapeutic innovations in atopic disease management befallen in the recent years in terms of personalized/precision medicine.
Antibodies, Monoclonal
;
Diagnostic Errors
;
Disease Management
;
Humans
;
Hypersensitivity*
;
Omalizumab
;
Pathology
;
Precision Medicine*
;
Prevalence
6.Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.
Jing LI ; Jian KANG ; Changzheng WANG ; Jing YANG ; Linda WANG ; Ioannis KOTTAKIS ; Michael HUMPHRIES ; Nanshan ZHONG
Allergy, Asthma & Immunology Research 2016;8(4):319-328
PURPOSE: Omalizumab is the preferred add-on therapy for patients with moderate-to-severe persistent allergic asthma and has demonstrated efficacy and safety in various ethnicities. This study evaluated the efficacy and safety of omalizumab in Chinese patients with moderate-to-severe allergic asthma. METHODS: This randomized, double-blind, parallel-group, placebo-controlled, phase III study assessed lung function, quality of life, asthma control, and safety of omalizumab after 24-week therapy in Chinese patients (18-75 years of age). RESULTS: A total of 616 patients were randomized (1:1) to omalizumab or placebo. The primary endpoint, least squares mean treatment difference (LSM-TD) in morning peak expiratory flow (PEF) (omalizumab vs placebo), at Weeks >20-24 was 8.85 L/min (Full analysis set; P=0.062). Per-protocol analysis set showed significant improvements with LSM-TD of 11.53 L/min in mean mPEF at Weeks >20-24 (P=0.022). The FEV1 % predicted was significantly improved with omalizumab vs placebo from 8 to 24 weeks (after 24-week treatment: LSM-TD=4.12%; P=0.001). At Week 24, a higher proportion of omalizumab-treated patients achieved clinically relevant improvements in standardized AQLQ (58.2% vs 39.3%; LSM=0.51 vs 0.10; P<0.001) and ACQ (49.5% vs 35.5%; LSM=-0.51 vs -0.34; P=0.002) scores vs placebo. Total and nighttime symptom scores reduced significantly with omalizumab vs placebo (LSM-TD=-0.21, P=0.048 and -0.12, P=0.011, respectively). Although the study was not powered to study differences in exacerbation rates (P=0.097), exacerbations in winter months were less frequent in the omalizumab vs placebo group (2 vs 21). Adverse event and severe adverse event rates were comparable between omalizumab and placebo. CONCLUSIONS: Omalizumab improves lung function, quality of life, and asthma control in Chinese patients with moderate-to-severe persistent allergic asthma and has a good safety profile.
Allergy and Immunology
;
Asian Continental Ancestry Group*
;
Asthma*
;
China
;
Humans
;
Least-Squares Analysis
;
Lung
;
Quality of Life*
;
Omalizumab
7.Recalcitrant Atopic Dermatitis Treated with Omalizumab.
Se Young PARK ; Mi Ra CHOI ; Jung Im NA ; Sang Woong YOUN ; Kyoung Chan PARK ; Chang Hun HUH
Annals of Dermatology 2010;22(3):349-352
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (FcepsilonRI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea.
Adult
;
Antibodies, Anti-Idiotypic
;
Antibodies, Monoclonal, Humanized
;
Binding Sites
;
Dermatitis, Atopic
;
Humans
;
Immunoglobulin E
;
Korea
;
Omalizumab
8.Oral Immunotherapy for Food Allergy: Towards a New Horizon.
Evelyne KHORIATY ; Dale T UMETSU
Allergy, Asthma & Immunology Research 2013;5(1):3-15
Food allergy has increased dramatically in prevalence over the past decade in westernized countries, and is now a major public health problem. Unfortunately for patients with food allergy, there is no effective therapy beyond food allergen avoidance, and rapid medical treatment for accidental exposures. Recently, oral immunotherapy (OIT) has been investigated as a treatment for this problem. In this review, we will discuss the progress in developing OIT for food allergy, including a novel approach utilizing Xolair (anti-IgE monoclonal antibody, omalizumab) in combination with OIT. This combination may enhance both the safety and efficacy of oral immunotherapy, and could lead to a widely available and safe therapy for food allergy.
Antibodies, Anti-Idiotypic
;
Antibodies, Monoclonal, Humanized
;
Food Hypersensitivity
;
Humans
;
Immunotherapy
;
Prevalence
;
Public Health
;
Omalizumab
9.Emerging Therapies in Chronic Spontaneous Urticaria
Allergy, Asthma & Immunology Research 2019;11(4):470-481
Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.
Angioedema
;
Basophils
;
Biological Products
;
Histamine
;
Humans
;
Leukotrienes
;
Mast Cells
;
Omalizumab
;
Prostaglandins
;
Urticaria
10.Omalizumab in recurring larynx angioedema: a case report
Ayse Bilge OZTURK ; Emek KOCATURK
Asia Pacific Allergy 2014;4(2):129-130
Angioedema with swelling of larynx is a serious allergic reaction and can be life-threatening. It can occur after exposure to various triggers and usually it is very difficult for the patient and the doctor to find the trigger and maintain complete remission. In idiopathic recurring angioedema presenting with frequent attacks, prophylaxis with H₁ antihistamines recommended. However, not all patients respond to antihistamines. Omalizumab is an anti-immunoglobulin (Ig)-E-Ig-G antibody approved for the treatment of asthma and also effective treatment in chronic spontaneous urticaria. We report a 47-year-old male patient with severe idiopathic angioedema controlled by corticosteroid and proggressed after discontining of corticosteroid because of its side effects. Omalizumab at a dose of 300 mg every 4 weeks was administrated and omalizumab provided a rapid clinical response after first injection. During the 4 months of omalizumab therapy, he had no further attacks and any other treatment needs. After 3 months of stopping omalizumab therapy, during the 4-week period he had two mild lip swelling in his lips that resolved with antihistamines.
Angioedema
;
Asthma
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Larynx
;
Lip
;
Male
;
Middle Aged
;
Omalizumab
;
Urticaria